AbbVie
ABBV
$250.94
-2.51%
AbbVie is a global biopharmaceutical company focused on immunology, oncology, neuroscience, and aesthetics, with key products including Skyrizi, Rinvoq, Botox, and Imbruvica. As a top-tier pharmaceutical firm spun off from Abbott in 2013, it has established itself as a Dividend King with a robust pipeline and a dominant position in immunology. The current investor narrative centers on AbbVie's successful post-Humira transition, driven by rapid growth of Skyrizi and Rinvoq, strategic acquisitions like Apogee Therapeutics to bolster its pipeline, and its ability to sustain dividend growth amid patent expirations.…
ABBV
AbbVie
$250.94
Related headlines
ABBV 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on AbbVie's 12-month outlook, with a consensus price target around $268.68 and implied upside of +7.1% versus the current price.
Average Target
$268.68
0 analysts
Implied Upside
+7.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$200 - $328
Analyst target range
AbbVie is covered by 28 analysts, with a consensus recommendation of 'Buy' (mean rating 1.74 on a 1-5 scale) and an average target price of $267.79. This implies approximately 3.3% upside from the current price of $259.36. The distribution leans bullish, with recent ratings from UBS (Neutral), BMO Capital (Outperform), Wells Fargo (Overweight), and B of A Securities (Buy) indicating broad institutional support. The target range spans from a low of $200.00 to a high of $328.00, representing a wide spread of $128. The high target of $328 implies 26.5% upside and likely assumes successful pipeline execution (e.g., Apogee acquisition, weight-loss drugs) and margin expansion. The low target of $200 implies 22.9% downside, pricing in risks such as FDA setbacks (e.g., TrenibotE rejection), competitive pressure, or slower-than-expected Humira replacement. The wide spread signals high uncertainty around the pace of growth and pipeline success, but the consensus remains bullish, with no recent downgrades and several reaffirmations of Overweight/Buy ratings.
Drowning in data?
Find the real signal!
Bulls vs Bears: ABBV Investment Factors
AbbVie presents a compelling bull case centered on its successful post-Humira transition, with Skyrizi and Rinvoq driving accelerating revenue growth and a forward P/E at a discount to peers. The company's strong free cash flow, low beta, and robust pipeline support a defensive growth profile. However, bears point to elevated trailing P/E due to earnings volatility, high debt levels, and margin compression from R&D spending. The FDA rejection for TrenibotE and wide analyst target range add uncertainty. The bull case currently has stronger evidence given the revenue acceleration and reasonable forward valuation, but the key tension is whether the company can sustain margin improvement and pipeline execution to justify the premium. The single most important factor is the trajectory of Skyrizi and Rinvoq sales growth relative to Humira's decline, which will determine if the forward P/E discount is warranted.
Bullish
- Revenue acceleration driven by Skyrizi and Rinvoq: Q1 2026 revenue grew 12.4% YoY to $15.0B, accelerating from 10.9% in Q4 2025 and 6.1% in Q3 2025. Skyrizi ($4.48B) and Rinvoq ($2.12B) are successfully offsetting Humira's decline ($688M), demonstrating a successful post-Humira transition.
- Attractive forward P/E discount to peers: Forward P/E of 15.9x is a 12% discount to the drug manufacturers industry average of ~18x. This valuation implies the market is not fully pricing in the growth trajectory, offering upside if earnings materialize as expected.
- Strong free cash flow generation: Trailing free cash flow of $20.9B provides ample liquidity for debt servicing, dividends, and acquisitions. The free cash flow yield of 5.1% supports the company's ability to maintain and grow its dividend, a key attraction for income investors.
- Robust pipeline and strategic acquisitions: The $10.9B Apogee Therapeutics acquisition bolsters the immunology pipeline, while the company is advancing weight-loss and eczema drugs. Analyst high target of $328 implies 26.5% upside, reflecting optimism on pipeline success.
Bearish
- Elevated trailing P/E from earnings volatility: Trailing P/E of 96.4x is distorted by one-time charges and depressed net income ($699M in Q1 2026). While forward P/E is lower, the gap signals earnings normalization risk; any miss on EPS estimates could lead to multiple compression.
- High debt and negative equity: Debt-to-equity of -21.1 reflects negative shareholders' equity due to aggressive share buybacks. Although cash flow is strong, the current ratio of 0.67 indicates potential liquidity stress if operating cash flow weakens.
- FDA rejection for TrenibotE: In April 2026, AbbVie received an FDA rejection for TrenibotE due to manufacturing issues. While not a scientific failure, it delays a potential growth driver and highlights regulatory risk in the aesthetics segment.
- Wide analyst target range signals uncertainty: Analyst targets range from $200 (22.9% downside) to $328 (26.5% upside), a spread of $128. This wide dispersion reflects high uncertainty around pipeline execution and competitive dynamics, particularly in immunology and weight-loss.
ABBV Technical Analysis
AbbVie is in a sustained uptrend, with the stock up 35.9% over the past year and currently trading at 99.1% of its 52-week range ($187.62 to $261.64). The price sits near the 52-week high of $261.64, reflecting strong momentum and investor optimism, though it also suggests the stock may be overextended in the near term. The 1-year relative strength versus SPY is +19.4%, indicating significant outperformance. Short-term momentum is accelerating, with the stock gaining 10.4% in the past month and 30.5% over the past three months, outpacing the S&P 500's 0.8% and 3.5% gains, respectively. This divergence from the broader market signals strong company-specific catalysts, such as pipeline progress and acquisition news, driving the rally. The 1-month relative strength of +9.6% confirms near-term bullish momentum. Key support lies at the 52-week low of $187.62, while resistance is at the recent high of $261.64. A breakout above $261.64 could open the door to further upside, while a breakdown below $187.62 would signal a trend reversal. With a beta of 0.28, AbbVie is significantly less volatile than the market, making it a defensive holding with lower risk for drawdowns.
Beta
0.28
0.28x market volatility
Max Drawdown
-19.2%
Largest decline past year
52-Week Range
$190-$267
Price range past year
Annual Return
+32.8%
Cumulative gain past year
| Period | ABBV Return | S&P 500 |
|---|---|---|
| 1m | -0.0% | +0.2% |
| 3m | +21.5% | +3.7% |
| 6m | +12.5% | +8.0% |
| 1y | +32.8% | +18.2% |
| ytd | +9.4% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ABBV Fundamental Analysis
AbbVie's revenue trajectory is accelerating, with Q1 2026 revenue of $15.0 billion growing 12.4% year-over-year, up from 10.9% growth in Q4 2025 and 6.1% in Q3 2025. The growth is driven by immunology blockbusters Skyrizi ($4.48B) and Rinvoq ($2.12B), which are offsetting declining Humira sales ($688M). The aesthetics segment, including Botox Cosmetic ($668M) and Botox Therapeutic ($1.01B), provides additional diversification. This multi-year growth acceleration supports the investment case for a successful post-Humira transition. Profitability is solid but uneven: Q1 2026 net income was $699 million (net margin 4.7%), down from $1.82 billion in Q4 2025 (net margin 10.9%) due to higher operating expenses and acquisition-related costs. Gross margin remains healthy at 71.9% in Q1 2026, consistent with the 70.2% trailing twelve-month average. The operating margin of 31.6% in Q1 2026 is strong, though below the 34.9% in Q4 2025, indicating some margin compression from R&D investment. AbbVie's balance sheet is leveraged but manageable: debt-to-equity is -21.1 (negative equity due to share buybacks), but the company generated $20.9 billion in trailing free cash flow, providing ample liquidity. The current ratio of 0.67 is low, but strong operating cash flow ($3.83B in Q1 2026) and a free cash flow yield of 5.1% (based on market cap) indicate robust cash generation to service debt and fund dividends.
Quarterly Revenue
$15.0B
2026-03
Revenue YoY Growth
+12.4%
YoY Comparison
Gross Margin
71.9%
Latest Quarter
Free Cash Flow
$20.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ABBV Overvalued?
Since net income is positive ($699M in Q1 2026), the trailing P/E ratio of 96.4x is the primary metric, but it is distorted by one-time charges; the forward P/E of 15.9x is more indicative, implying the market expects normalized earnings growth. The gap between trailing and forward P/E suggests the market anticipates a sharp earnings recovery, supported by analyst estimates of $21.01 EPS for the next fiscal year. Compared to the drug manufacturers industry, AbbVie's forward P/E of 15.9x is at a discount to the sector average of approximately 18x (based on industry data), representing a 12% discount. This discount may be justified by the perceived risk of Humira's decline and high debt levels, but it also reflects the market's skepticism about sustained growth. Historically, AbbVie's trailing P/E has ranged from 14.8x (Q4 2021) to 581.8x (Q3 2025), with the current 96.4x near the high end due to earnings volatility. The forward P/E of 15.9x is near the lower end of its historical range, suggesting the stock is reasonably valued relative to normalized earnings and may offer upside if growth materializes.
PE
96.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 15x~139x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
26.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: AbbVie's balance sheet is leveraged with a debt-to-equity ratio of -21.1, reflecting negative equity from share buybacks. While trailing free cash flow of $20.9B provides coverage, the current ratio of 0.67 suggests limited short-term liquidity. Net margin declined from 10.9% in Q4 2025 to 4.7% in Q1 2026 due to higher operating expenses and acquisition-related costs. The company's reliance on Skyrizi and Rinvoq for growth concentration risk, as these two drugs now represent a significant portion of revenue. Any clinical or competitive setback could materially impact earnings.
Market & Competitive Risks: AbbVie's forward P/E of 15.9x is at a discount to the industry average of 18x, but the trailing P/E of 96.4x highlights earnings volatility that could lead to multiple compression if growth disappoints. The stock's beta of 0.28 indicates low market correlation, but sector rotation away from defensive pharma could pressure the stock. Competitive threats include biosimilars to Humira and emerging therapies from Eli Lilly and others in immunology and weight-loss. The FDA rejection for TrenibotE in April 2026 underscores regulatory risk, while new drug tariffs could impact international sales.
Worst-Case Scenario: A combination of slower-than-expected Skyrizi/Rinvoq growth, further FDA setbacks, and margin compression could drive the stock to the analyst low target of $200, representing 22.9% downside from the current price of $259.36. In a severe scenario, a broader market downturn or patent cliff issues could push the stock to the 52-week low of $187.62, implying a loss of 27.7%. The historical max drawdown of -19.23% suggests that a 20-30% decline is within the realm of possibility if pipeline catalysts fail.
